Hyperway

Chengdu Haibowei Pharmaceutical Co., Ltd. was founded in January 2019. As a new type of biopharmaceutical company driven by research and development, it integrates innovative drug development with high-end generic drug development in its business model. Hyperway is committed to building world-leading platforms for small molecule innovative drug R&D, high-end active pharmaceutical ingredient R&D, and technically challenging generic drug R&D. By fully aligning with global pharmaceutical industry trends, the company aims to develop safe, effective, high-quality, and cost-effective drugs to benefit patients both in China and internationally.Hyperway has a top-tier R&D team and scientific advisory team. Core members possess extensive experience in drug R&D and management from working at Fortune 500 companies or well-known pharmaceutical enterprises in China. The company has successfully developed several world-class novel clinical drugs and multiple high-end generic drugs (including the first Chinese generics of international blockbuster drugs).